A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
Study of Drug in Patients with Progressive Supranuclear Palsy
Sponsor: AbbVie, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR2561
U.S. Govt. ID: NCT02985879
Contact: Evelyn D. Dominguez: 212-305-2371 / edd5@cumc.columbia.edu
Additional Study Information: This is a study for persons with a diagnosis of Progressive Supranuclear Palsy, involving an experimental treatment.
This study is closed
Lawrence Honig, MD, PhD
Do You Qualify?
Are you 40 years of age or older? Yes No
Do you have Progressive Supranuclear Palsy (PSP)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Evelyn D. Dominguez